The beating heart of melanomas: A minor subset of cancer cells sustains tumor growth

Oncotarget

Volumn 2, Issue 4, 2011, Pages 313-320

  Schmidt, Patrick ^a   Abken, Hinrich ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adoptive cell therapy; Cancer stem cell; Melanoma

Indexed keywords

CD20 ANTIBODY; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CARCINOGENESIS; CELL DIVISION; CELL LINEAGE; CELL RENEWAL; CELL SUBPOPULATION; CYTOTOXICITY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MELANOMA; MELANOMA CELL; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPIC PLASTICITY; STEM CELL TRANSPLANTATION; TUMOR GROWTH; TUMOR RESISTANCE; XENOTRANSPLANTATION; ANIMAL; BIOLOGICAL MODEL; CELL GROWTH; DRUG DELIVERY SYSTEM; DRUG EFFECT; EXPERIMENTAL THERAPY; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; SKIN TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; DRUG DELIVERY SYSTEMS; HUMANS; MELANOMA; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; SKIN NEOPLASMS; THERAPIES, INVESTIGATIONAL;

EID: 80052420861     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.259     Document Type: Article

References (52)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
2. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467:1114-1117.
3. Zhou B-BS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009, 8:806-823.
4. Schmidt P, Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc. Natl. Acad. Sci. U.S.A 2011, 108:2474-2479.
5. Pierce GB, Wallace C. Differentiation of malignant to benign cells. Cancer Res 1971, 31:127-134.
6. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988, 48:1996-2004.
7. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med 1997, 3:730-737.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A 2003, 100:3983-3988.
10. Dick JE. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
11. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med 2011, 17:313-319.
12. Marotta LLC, Polyak K. Cancer stem cells: a model in the making. Curr. Opin. Genet. Dev 2009, 19:44-50.
13. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324:1670-1673.
14. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 2006, 66:1891-1895; discussion 1890.
15. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution. Cell 2009, 138:822-829.
16. Shackleton M, Quintana E. Progress in understanding melanoma propagation. Mol Oncol 2010, 4:451-457.
17. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, Butler PD, Yang GP, Joshua B, Kaplan MJ, Longaker MT, Weissman IL. Human melanomainitiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
18. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
19. Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of Melanoma Cells Capable of Propagating Tumors from a Single Cell. Cancer Research 2010, 70:388-397.
20. Cho RW, Wang X, Diehn M, Shedden K, Chen GY, Sherlock G, Gurney A, Lewicki J, Clarke MF. Isolation and molecular characterization of cancer stem cells in MMTVWnt-1 murine breast tumors. Stem Cells 2008, 26:364-371.
21. Vaillant F, Asselin-Labat M-L, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008, 68:7711-7717.
22. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM. Identification of tumorinitiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68:4674-4682.
23. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008, 452:650-653.
24. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
25. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
26. Deshpande AJ, Cusan M, Rawat VPS, Reuter H, Krause A, Pott C, Quintanilla-Martinez L, Kakadia P, Kuchenbauer F, Ahmed F, Delabesse E, Hahn M, Lichter P, Kneba M, Hiddemann W, Macintyre E, Mecucci C, Ludwig W-D, Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia. Cancer Cell 2006, 10:363-374.
27. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008:329-342.
28. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005, 65:9328-9337.
29. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
30. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PWK, Lam CT, Poon RTP, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
31. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
32. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
33. Joo KM, Kim SY, Jin X, Song SY, Kong D-S, Lee J-I, Jeon JW, Kim MH, Kang BG, Jung Y, Jin J, Hong S-C, Park W-Y, Lee D-S, Kim H, Nam D-H. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest 2008, 88:808-815.
34. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, McCormick PC, Canoll P, Bruce JN. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008, 62:505-514; discussion 514-515.
35. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010, 17:362-375.
36. Dalerba P, Dylla SJ, Park I-K, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A 2007, 104:10158-10163.
37. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
38. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CAM. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur. J. Cancer 2007, 43:935-946.
39. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
40. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth. Cell 2010, 141:583-594.
41. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong K-K, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
42. Hoek KS, Goding CR. Cancer stem cells versus phenotypeswitching in melanoma. Pigment Cell Melanoma Res 2010, 23:746-759.
43. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317:337.
44. Dingli D, Michor F. Successful therapy must eradicate cancer stem cells. Stem Cells 2006, 24:2603-2610.
45. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M, Johnson M, Gajewski TF. Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. Ann. Oncol 2004, 15:1109-1114.
46. Kotz J. Stemming melanoma. Science-Business eXchange 2011, 4.
47. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
48. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, Taniguchi S, Shultz LD, Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol 2010, 28:275-280.
49. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst 2008, 100:672-679.
50. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
51. Takata M, Morita R, Takehara K. Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis. Int. J. Cancer 2000, 85:492-497.
52. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.